HUP0001443A2 - 5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds, pharmaceutical compositions thereof and process for preparing them - Google Patents
5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds, pharmaceutical compositions thereof and process for preparing themInfo
- Publication number
- HUP0001443A2 HUP0001443A2 HU0001443A HUP0001443A HUP0001443A2 HU P0001443 A2 HUP0001443 A2 HU P0001443A2 HU 0001443 A HU0001443 A HU 0001443A HU P0001443 A HUP0001443 A HU P0001443A HU P0001443 A2 HUP0001443 A2 HU P0001443A2
- Authority
- HU
- Hungary
- Prior art keywords
- compounds
- trisubstituted
- arylalkyl
- heteroaryl
- aryl
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- -1 5,6,7-trisubstituted-4-amino-pyrido[2,3-d]pyrimidine compounds Chemical class 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 239000003121 adenosine kinase inhibitor Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 230000008058 pain sensation Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
A találmány tárgya (II) általános képletű 5,6,7-triszubsztituált-4-amino-pirido[2,3-d]pirimidin vegyületek, ahol a képletben R1 és R2 egymástól függetlenül lehet hidrogénatom, rövid szénláncúalkil-, aril-alkil- vagy acilcsoport, vagy a kapcsolódónitrogénatommal együtt 5-7-tagú, adott esetben 1-3 továbbiheteroatomot, mégpedig nitrogén-, oxigén- és/vagy kénatomot tartalmazógyűrűt képez; R3 és R4 egymástól függetlenül lehet rövid szénláncú alkil-, alkenil-,alkinil- vagy cikloalkilcsoport, aril-, aril-alkil-, heteroaril- vagyheterociklusos csoport; és R5 jelentése aril-, heteroaril- vagyheterociklusos csoport; valamint a vegyületeket gyógyászatimennyiségben és gyógyászatilag elfogadható hordozót tartalmazóadenozin kináz gátló gyógyászati készítmények. Fenti vegyületek ígyagyi ischémia, epilepszia, fájdalom, fájdalomérzet, gyulladás ésszepszis elleni gyógyszerkészítmények előállítására alkalmazhatók. Atalálmány kiterjed a vegyületek előállítására is. ÓThe subject of the invention is 5,6,7-trisubstituted-4-amino-pyrido[2,3-d]pyrimidine compounds of general formula (II), where R1 and R2 in the formula can independently be a hydrogen atom, lower alkyl, arylalkyl- or an acyl group, or forms a 5-7-membered ring together with the attached nitrogen atom, optionally containing 1-3 additional heteroatoms, namely nitrogen, oxygen and/or sulfur atoms; R3 and R4 can independently be a lower alkyl, alkenyl, alkynyl or cycloalkyl group, an aryl, arylalkyl, heteroaryl or heterocyclic group; and R 5 is aryl, heteroaryl or heterocyclic; and adenosine kinase inhibitor pharmaceutical preparations containing the compounds in a pharmaceutical amount and a pharmaceutical acceptable carrier. The above compounds can thus be used for the production of medicinal preparations against cerebral ischemia, epilepsy, pain, pain sensation, inflammation and sepsis. The invention also covers the production of compounds. HE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84348497A | 1997-04-16 | 1997-04-16 | |
| PCT/US1998/007201 WO1998046604A1 (en) | 1997-04-16 | 1998-04-13 | 5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0001443A2 true HUP0001443A2 (en) | 2000-10-28 |
| HUP0001443A3 HUP0001443A3 (en) | 2001-01-29 |
Family
ID=25290123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0001443A HUP0001443A3 (en) | 1997-04-16 | 1998-04-13 | 5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds, pharmaceutical compositions thereof and process for preparing them |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0975633A1 (en) |
| JP (1) | JP2001520654A (en) |
| KR (1) | KR20010006462A (en) |
| CN (1) | CN1252069A (en) |
| AR (1) | AR012437A1 (en) |
| AU (1) | AU741033B2 (en) |
| BG (1) | BG103853A (en) |
| BR (1) | BR9809056A (en) |
| CA (1) | CA2286592A1 (en) |
| CO (1) | CO4940470A1 (en) |
| HU (1) | HUP0001443A3 (en) |
| IL (1) | IL131617A0 (en) |
| NO (1) | NO995035L (en) |
| NZ (1) | NZ337125A (en) |
| PL (1) | PL336265A1 (en) |
| SK (1) | SK140099A3 (en) |
| TR (1) | TR199902550T2 (en) |
| WO (1) | WO1998046604A1 (en) |
| ZA (1) | ZA983175B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001057040A1 (en) * | 2000-02-03 | 2001-08-09 | Abbott Laboratories | 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds |
| JP4064818B2 (en) | 2001-02-12 | 2008-03-19 | エフ．ホフマン−ラ ロシュ アーゲー | 6-substituted pyrido-pyrimidines |
| CN107744520A (en) * | 2017-10-25 | 2018-03-02 | 南京多宝生物科技有限公司 | Pyrimidines are preparing the application in promoting small bowel peristalsis medicine |
| CN112209924B (en) * | 2019-07-09 | 2022-04-05 | 中国科学院天津工业生物技术研究所 | Selective adenosine A1Receptor antagonists |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB774094A (en) * | 1953-01-02 | 1957-05-08 | Wellcome Found | Improvements in or relating to pyrimidine compounds |
| IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
-
1998
- 1998-04-13 CN CN98804117A patent/CN1252069A/en active Pending
- 1998-04-13 TR TR1999/02550T patent/TR199902550T2/en unknown
- 1998-04-13 JP JP54408398A patent/JP2001520654A/en active Pending
- 1998-04-13 NZ NZ337125A patent/NZ337125A/en unknown
- 1998-04-13 BR BR9809056-9A patent/BR9809056A/en not_active IP Right Cessation
- 1998-04-13 KR KR1019997009552A patent/KR20010006462A/en not_active Application Discontinuation
- 1998-04-13 HU HU0001443A patent/HUP0001443A3/en unknown
- 1998-04-13 SK SK1400-99A patent/SK140099A3/en unknown
- 1998-04-13 CA CA002286592A patent/CA2286592A1/en not_active Abandoned
- 1998-04-13 AU AU71080/98A patent/AU741033B2/en not_active Ceased
- 1998-04-13 WO PCT/US1998/007201 patent/WO1998046604A1/en not_active Application Discontinuation
- 1998-04-13 EP EP98918091A patent/EP0975633A1/en not_active Withdrawn
- 1998-04-13 IL IL13161798A patent/IL131617A0/en unknown
- 1998-04-13 PL PL98336265A patent/PL336265A1/en unknown
- 1998-04-15 AR ARP980101734A patent/AR012437A1/en unknown
- 1998-04-15 ZA ZA983175A patent/ZA983175B/en unknown
- 1998-04-16 CO CO98020978A patent/CO4940470A1/en unknown
-
1999
- 1999-10-15 NO NO995035A patent/NO995035L/en not_active Application Discontinuation
- 1999-11-03 BG BG103853A patent/BG103853A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0001443A3 (en) | 2001-01-29 |
| CN1252069A (en) | 2000-05-03 |
| CA2286592A1 (en) | 1998-10-22 |
| TR199902550T2 (en) | 2000-04-21 |
| AU741033B2 (en) | 2001-11-22 |
| BG103853A (en) | 2000-06-30 |
| EP0975633A1 (en) | 2000-02-02 |
| BR9809056A (en) | 2000-08-01 |
| CO4940470A1 (en) | 2000-07-24 |
| JP2001520654A (en) | 2001-10-30 |
| NO995035L (en) | 1999-12-15 |
| PL336265A1 (en) | 2000-06-19 |
| IL131617A0 (en) | 2001-01-28 |
| KR20010006462A (en) | 2001-01-26 |
| SK140099A3 (en) | 2000-05-16 |
| AR012437A1 (en) | 2000-10-18 |
| AU7108098A (en) | 1998-11-11 |
| NO995035D0 (en) | 1999-10-15 |
| ZA983175B (en) | 1998-10-21 |
| NZ337125A (en) | 2001-06-29 |
| WO1998046604A1 (en) | 1998-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0300641A2 (en) | Triazaspiro[5.5]undecane derivatives and pharmaceutical compositions containing the same as the active ingredient | |
| HUP0300082A2 (en) | 7- and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline derivatives, process for their preparation and use and pharmaceutical compositions containing them | |
| UA66825C2 (en) | Azapolycyclic compounds condensed with aryl | |
| HUP0103413A2 (en) | Heterocyclic compounds as inhibitors of rotamase enzymes, their intermediates, process for their preparation and pharmaceutical compositions containing them | |
| HUP0401083A2 (en) | 4-amino-6-phenyl-pyrrolo [2,3-d] pyrimidine derivatives, pharmaceutical compositions containing them and process for the preparation of the compounds | |
| HUP0001802A2 (en) | Pyrazine derivatives, process for producing them and pharmaceutical compositions containing them | |
| HUP0402336A2 (en) | Thieno[2,3-d]pyrimidine-2,4-dione derivatives, process for their preparation, their use in the modulation of autoimmune disease and pharmaceutical compositions containing them | |
| HUP0301801A2 (en) | Imidazo[1,2-a]pyrazine derivatives and pharmaceutical compositions containing them | |
| HUP0204474A2 (en) | 1h-imidazopyridine derivatives, pharmaceutical compositions containing them and their use | |
| HUP0001285A2 (en) | Pyrrolidine derivatives as protease inhibitors, process for producing them and pharmaceutical compositions containing them | |
| HUT70505A (en) | Pyrrolo[2,3-d]pyrimidine derivatives, pharmaceutical compositions containing them and process for preparing them | |
| HUP0203450A2 (en) | Pyrazolo '4,3-d! pyrimidine derivatives, process for their preparation and pharmaceutical compositions containing them and their use | |
| HUP0300565A2 (en) | 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors, their use, process for their preparation and pharmaceutical compositions containing them | |
| PL335696A1 (en) | Substituted 4-arylmethylene-2-imino-2,3-dihydrothiasoles and their derivatives as well as their pharmaceutical application | |
| WO2004055005A8 (en) | Novel compounds having selective inhibiting effect at gsk3 | |
| HUP0001434A2 (en) | 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds, pharmaceutical compouads thereof and process for their preparation | |
| GEP20012439B (en) | Aniline Derivatives Having Nitrogen Monoxide Synthase Inhibitory Activity and Pharmaceutical Compositions Containing the Same | |
| SE9702564D0 (en) | New compounds | |
| HUP0100328A2 (en) | Novel triazolo(4,5-d)pyrimidine compounds, and pharmaceutical compositions containing the compounds | |
| HUP0104033A2 (en) | Benzoylpyridazines, medicaments containing the compounds, process for their preparation and their use | |
| YU64400A (en) | Aryl fused azapolycyclic compounds | |
| TW429255B (en) | Pyrazine compounds having treatment of central nervous system diseases and disorders | |
| IL112098A0 (en) | Sulfamate derivatives and pharmaceutical compositions containing them | |
| HUP0301587A2 (en) | 5-aminoalkyl-pyrazolo[4,3-d]pyrimidines with a phosphodiesterase v-inhibiting effect, pharmaceutical compositions containing them and processes for their preparations | |
| HUP0001443A2 (en) | 5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds, pharmaceutical compositions thereof and process for preparing them |